L
Lucio Crinò
Researcher at University of Perugia
Publications - 304
Citations - 31035
Lucio Crinò is an academic researcher from University of Perugia. The author has contributed to research in topics: Lung cancer & non-small cell lung cancer (NSCLC). The author has an hindex of 62, co-authored 293 publications receiving 27096 citations. Previous affiliations of Lucio Crinò include University of Turin.
Papers
More filters
Journal ArticleDOI
Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer
Julie R. Brahmer,Karen L. Reckamp,Paul Baas,Lucio Crinò,Wilfried Eberhardt,Elena Poddubskaya,Scott J. Antonia,Adam Pluzanski,Everett E. Vokes,Esther Holgado,David M. Waterhouse,Neal Ready,Justin F. Gainor,Osvaldo Arén Frontera,Libor Havel,Martin Steins,Marina Chiara Garassino,Joachim G.J.V. Aerts,Manuel Domine,Luis Paz-Ares,Martin Reck,Christine Baudelet,Christopher T. Harbison,Brian Lestini,David R. Spigel +24 more
TL;DR: Among patients with advanced, previously treated squamous-cell NSCLC, overall survival, response rate, and progression-free survival were significantly better with nivolumab than with docetaxel, regardless of PD-L1 expression level.
Journal ArticleDOI
Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
Alice T. Shaw,Dong Wan Kim,Kazuhiko Nakagawa,Takashi Seto,Lucio Crinò,Myung-Ju Ahn,Tommaso De Pas,Benjamin Besse,Benjamin Solomon,Fiona H Blackhall,Yi-Long Wu,Michael Thomas,Kenneth J. O'Byrne,Denis Moro-Sibilot,D. Ross Camidge,Tony Mok,Vera Hirsh,Gregory J. Riely,Shrividya Iyer,V. Tassell,Anna Polli,Keith D. Wilner,Pasi A. Jänne +22 more
TL;DR: Crizotinib is superior to standard chemotherapy in patients with previously treated, advanced non-small-cell lung cancer with ALK rearrangement and greater improvement in global quality of life with crizotinIB than with chemotherapy.
Journal ArticleDOI
Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non–Small-Cell Lung Cancer
Federico Cappuzzo,Fred R. Hirsch,Elisa Rossi,Stefania Bartolini,Giovanni Luca Ceresoli,Lynne T. Bemis,Jerry Haney,Samir E. Witta,Kathleen D. Danenberg,I. Domenichini,Vienna Ludovini,Elisabetta Magrini,Vanesa Gregorc,Claudio Doglioni,Angelo Sidoni,Maurizio Tonato,Wilbur A. Franklin,Lucio Crinò,Paul A. Bunn,Marileila Varella-Garcia +19 more
TL;DR: High EGFR gene copy number identified by FISH may be an effective molecular predictor for gefitinib efficacy in advanced NSCLC and independent of EGFR assessment method, EGFR+/P-Akt+ patients had a statistically significantly better outcome than EGFR-, P- akt-, or EGFR-/Akt- patients.
Journal ArticleDOI
Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Compared With Infusional Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) As First-Line Treatment for Metastatic Colorectal Cancer: The Gruppo Oncologico Nord Ovest
Alfredo Falcone,Sergio Ricci,Isa Brunetti,Elisabetta Pfanner,Giacomo Allegrini,C. Barbara,Lucio Crinò,Giovanni Benedetti,W. Evangelista,Laura Fanchini,Enrico Cortesi,V. Picone,Stefano Vitello,Silvana Chiara,Cristina Granetto,Gianfranco Porcile,Luisa Fioretto,Cinzia Orlandini,Michele Andreuccetti,Gianluca Masi +19 more
TL;DR: The FOLFOXIRI regimen improves RR, PFS, and OS compared with FOLFIRI, with an increased, but manageable, toxicity in patients with metastatic colorectal cancer with favorable prognostic characteristics.
Journal ArticleDOI
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial
Vincent A. Miller,Vincent A. Miller,Vera Hirsh,Jacques Cadranel,Yuh Min Chen,Keunchil Park,Sang We Kim,Caicun Zhou,Wu Chou Su,M. Wang,Yan Sun,Dae Seog Heo,Lucio Crinò,Eng Huat Tan,Tsu Yi Chao,Mehdi Shahidi,X.J. Cong,Robert M. Lorence,James Chih-Hsin Yang +18 more
TL;DR: The findings for progression-free survival and response to treatment suggest that afatinib could be of some benefit to patients with advanced lung adenocarcinoma who have failed at least 12 weeks of previous EGFR tyrosine-kinase inhibitor treatment.